IDH2 and astrocytoma (excluding glioblastoma): No significant differences were noted in recurrence/progression-free survival between the subclonal and clonal IDH-mutant astrocytomas, although there were nonsignificant trends toward shorter progression-free survival in subclonal grade 3 (38 vs. 114 months; P = .0955) and grade 4 (17.4 vs. 36 months; P = .1725) astrocytomas compared to grade 3 and 4 clonal IDH-mutant astrocytomas.